Sensitive skin in the city: Galderma’s China study links pollution, stress, and poor sleep to lasting damage

Why is Galderma presenting a real-world study on sensitive skin at the European Academy of Dermatology and Venereology Congress 2025?

Galderma (SIX: GALD), the Swiss dermatology-focused company, has released findings from what it calls the first real-world clinical study assessing the biological impact of lifestyle and environment on sensitive skin. The study, conducted in China with the support of the Galderma Global Sensitive Skincare Faculty (GSSF), will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress on September 19.

The results point to a clear link between modern urban living and worsened skin health, particularly among individuals already predisposed to sensitivity. The findings have been described by Galderma as “biological evidence” of what dermatologists have long suspected—that pollution, stress, and sleep disruption amplify the clinical burden of sensitive skin.

How significant is sensitive skin as a global condition, and why is it under-researched despite rising prevalence?

Sensitive skin affects up to 70% of people worldwide, with prevalence increasing by nearly 68% over the past two decades. Despite this scale, sensitive skin remains one of the least understood dermatological conditions because its symptoms are often self-reported and difficult to measure objectively.

Galderma and the GSSF positioned this new research as an attempt to bridge that gap by moving sensitive skin from a subjective complaint to a quantifiable biological condition. According to dermatologists involved, the study provides measurable markers—such as inflammation and oxidative stress—that prove sensitive skin responds differently to environmental stressors.

This builds on Galderma’s history of commissioning global epidemiological surveys and positioning sensitive skin as a clinical field deserving of better recognition, diagnosis, and treatment strategies.

What methodology did Galderma use in its Chinese study on urban versus traditional lifestyles?

The study enrolled 150 women aged 35–50, divided equally into three cohorts: individuals with sensitive skin living in urban environments, those with sensitive skin living in more traditional and less urbanized settings, and a third control group of individuals with non-sensitive skin in modern urban environments.

The assessment combined lifestyle indicators—such as exposure to air pollution, levels of psychological stress, and sleep quality—with biological measures obtained through tape-stripping analysis of the outermost skin layer, the stratum corneum. This method allowed researchers to track inflammation and oxidative stress at a molecular level, producing data that could be compared across groups.

Participants in urban settings were consistently found to have higher pollution exposure, greater reported stress levels, and poorer sleep quality compared with those in traditional environments.

What biological markers did the study identify as critical in worsening sensitive skin in modern environments?

The Galderma study highlighted three biological phenomena that make sensitive skin more vulnerable in modern environments: inflammation, oxidative stress, and photoaging.

Inflammation was measured through elevated levels of prostaglandin E2, a signaling molecule linked to immune activation. Participants with sensitive skin in urban settings recorded three times more inflammation compared to those in traditional settings. This inflammation manifests clinically as redness, discomfort, and barrier dysfunction.

Oxidative stress, which results from pollution and UV exposure, was also more pronounced. People with sensitive skin living in modern environments showed a 16% higher level of oxidative stress markers compared to those with non-sensitive skin. Galderma’s analysis suggested oxidative stress could be a central driver of sensitive skin overall, as consistently high levels were observed regardless of lifestyle.

Finally, visible evidence of photoaging, particularly the increased presence of dark spots, was found more often in individuals with sensitive skin. This suggests that environmental triggers accelerate skin damage, affecting both biological health and cosmetic appearance.

How are dermatology experts interpreting the link between modern lifestyles and sensitive skin conditions?

Dermatologists within the Global Sensitive Skincare Faculty indicated that the findings validate a growing consensus: sensitive skin is not only a subjective condition but also a measurable biological response.

They emphasized that modern urban living presents a “triple threat” for sensitive skin—pollution, stress, and inadequate sleep all act as compounding triggers that amplify inflammatory and oxidative pathways.

Institutional sentiment points to this being an important step in shifting sensitive skin from anecdotal observation to scientific recognition. For dermatology-focused companies like Galderma, this strengthens the case for expanded research funding, improved diagnostics, and tailored product development.

How does Galderma plan to leverage the study in its dermatology portfolio and patient education strategy?

Galderma is showcasing these findings at the EADV 2025 Congress as part of a broader effort to align science, education, and commercial opportunity. Alongside the study, the company will present five other sensitive skin research abstracts and host expert-led sessions around its flagship skincare brand, Cetaphil®.

The strategy reflects Galderma’s long-term positioning as a science-driven dermatology firm. By promoting research that quantifies the biological basis of sensitive skin, the company is building credibility that can extend to its product lines in dermatological skincare, therapeutic dermatology, and aesthetic injectables.

Industry observers note that this also represents an educational opportunity. With sensitive skin affecting a majority of the global population yet still being underdiagnosed, Galderma can lead in both raising awareness and offering evidence-backed solutions.

What does this mean for Galderma’s market position and investor perception in dermatology?

Galderma is listed on the SIX Swiss Exchange under the ticker GALD and markets itself as a pure-play dermatology leader. The company operates across nearly 90 countries, with a portfolio that spans therapeutic dermatology, skincare, and injectable aesthetics.

Institutional investors generally view dermatology as a fast-growing healthcare segment, supported by demographic factors such as aging populations, urbanization, and increased attention to personal wellness. Sensitive skin in particular represents a high-volume, high-engagement consumer segment, where scientific credibility and brand trust are key differentiators.

By producing quantifiable data on sensitive skin and linking it to modern living, Galderma may strengthen its ability to command premium positioning in both clinical and over-the-counter categories. Analysts expect that this type of evidence-driven marketing can support long-term sales growth for products like Cetaphil, while also enhancing Galderma’s reputation as a scientific innovator in dermatology.

What are the future implications of Galderma’s findings for sensitive skin research and dermatology care?

The study’s results are expected to have a ripple effect across the dermatology field. For clinicians, the evidence provides measurable biological markers that can support diagnosis and management strategies for sensitive skin. For researchers, it establishes a framework for linking lifestyle and environmental exposures to dermatological conditions.

Looking ahead, analysts anticipate further research into how oxidative stress and inflammation can be managed, possibly through both pharmacological interventions and lifestyle-focused dermatology care. The data may also encourage more precise segmentation of skincare solutions for urban populations compared with traditional or rural consumers.

For patients, the study could help elevate sensitive skin into a condition that garners more recognition, research funding, and treatment options, reducing the gap between its prevalence and its current underrepresentation in clinical literature.